Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a variety of important cellular functions. One of their important functions is to transfer DNA, RNA, and proteins to other cells.
For years, exosomes were considered to be transporters of cellular waste, but now they are becoming recognized for their critical role in cell-to-cell communication and transportation.
As a result, the exosome market is attracting growing investment, including the attention of industry behemoth Google Ventures.
Exosome Market Is Heating Up
Momentum in the exosome industry is heating up, with venture capital giant Google Ventures (GV) placing a major bet on the Evox Therapeutics in September 2018.
Evox Therapeutics Ltd, a leading exosome therapeutics company based in the UK, announced that it has raised £35.5 million (USD $45.4 million) in Series B financing. According to Evox Therapeutics, Redmile Group led the financing with significant new investments from GV (formerly Google Ventures) and Cowen Healthcare Investments.
Evox had previously secured £10 million as part of a Series A seed financing from Oxford Sciences Innovation (OSI).
Evox is an exosome therapeutics company focused on harnessing and utilizing the delivery capabilities of exosomes to achieve targeted small and large molecule delivery. The company has secured proprietary technology to modify exosomes for purposes of targeting drug delivery to organs of interest, such as the human brain and central nervous system (CNS).
When the term “exosome” is searched within the scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author, with 37 articles. Therefore, it is not surprising that Evox Therapeutic is utilizing exosome technology from the Karolinska Institute, as well as another leading research institution, Oxford University.
Exosome Venture Capital
On the venture capital front, exosome market activity has been accelerating in recent months.
For example, Exosome Diagnostics closed $60 million in Series B financing in January 2016, which it followed in July 2017 with $30 million in Series C financing. Similarly, Codiak Biosciences was launched in 2016 when the MD Anderson Cancer Center joined two venture capital firms to form the company with more than $80 million in series A and B financing. On November 29, 2017, Codiak BioSciences added another $76.5 million in Series C financing. In May 2017, ExCoBio Inc. raised US $11 million in a Series A funding round.
Exosome and Extracellular Vesicle (EV) Clinical Trials
In May 2018, Aegle announced that it will be the first extracellular vesicle (EV) company to be cleared by the FDA to enter clinical trials in humans.
The FDA cleared Aegle's IND application to initiate a clinical trial in severe second degree burn patients. The company plans to launch a Phase 1/2a clinical trial of its lead product AGLE-102 in late 2018.
Other companies leading the charge in the area of exosome therapeutics include Anjarium Biosciences, Capricor Therapeutics, Codiak Biosciences, Creative Medical Technology Holdings, Everkine Corporation, Evox Therapeutics, Exogenus Therapeutics, Kimera Labs, ReNeuron, and Unicyte AG, a subsidiary of Fresenius Medical Care.
Numerous life science companies have also launched tools and systems to support exosome research, including Beckman Coulter, Exiqon, System Biosciences (SBI), Lonza, Thermo Fisher, Qiagen, ZenBio, and more. In particular, Lonza made aggressive investments in the sector through its May 2017 acquisition of HansaBioMed Life Sciences and investment into Exosomics.
Similarly, techniques for large-scale clinical-grade manufacture of stem cell exosomes is becoming a focal point within the industry, as highlighted by a recent partnership between RoosterBio and Exopharm, as well as Lonza’s strategic acquisitions. VivaZome Therapeutics was also awarded a grant of $2.18M by the Australian government to support an exosome manufacturing project.
Get More Information
To characterize this rapidly maturing marketplace, BioInformant has released a 134-page market report titled The Market for Stem Cell Exosomes, which explores the growing demand for exosome therapeutics, diagnostics, research tools, consumer care products, and manufacturing technologies.
This comprehensive report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials. It also reveals market size data and segmentation, as well as little known metrics about exosome industry deal-making, clinical breakthroughs, strategic alliances, and more.
Access this global report to:
- Get educated about the rapidly evolving exosome market.
- Identify opportunities for exosome product development.
- Reveal the identities of competitors developing exosome products, diagnostics, and therapeutics.
- Access market size determinations, market segmentation, and 5-year projections through 2022.
- Determine company strategy or pursue external funding from investors.
- Make smarter decisions, faster.
- Could this report save you from one expensive strategy mistake?
- Could it help you to identify one new strategic partner or technology innovator?
- Could it reduce the time necessary to make decisions about company strategy by hours or days?
- Could it assist you with identifying one new investor favorable toward exosome investments?
If so, I am confident that this report will be a value resource to your group. Click the button below to view the report page on MarketResearch.com and learn more.
About the Author: Cade Hildreth, B.S., M.S., is Founder and President of BioInformant, the world’s first and only market research firm to specialize in the stem cell industry. BioInformant research has been cited by the Wall Street Journal, Xconomy, and AABB.